Welcome to our dedicated page for CERO THERAPEUTICS HOLDINGS SEC filings (Ticker: CERO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CERO THERAPEUTICS HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CERO THERAPEUTICS HOLDINGS's regulatory disclosures and financial reporting.
CERo Therapeutics Holdings, Inc. reported that the U.S. Food and Drug Administration granted Fast Track Designation to its lead investigational compound, CER-1236, for the treatment of Acute Myeloid Leukemia (AML). This regulatory status is intended to facilitate the development and review of therapies for serious conditions. The company disclosed this update in a current report and attached the related press release as an exhibit.
CERo Therapeutics Holdings, Inc. reports that Nasdaq has determined the company no longer meets the Nasdaq Capital Market’s minimum stockholders’ equity requirement of $2,500,000 under Rule 5550(b). Because the company is under a one-year mandatory panel monitor following a prior compliance issue, Nasdaq staff cannot grant an additional cure period.
The letter states that CERo’s securities are subject to suspension and delisting from Nasdaq on September 8, 2025, unless successfully appealed. The company requested a hearing on September 3, 2025, which stays any suspension and delisting while the appeal is pending. CERo plans to present a compliance plan that may include raising stockholders’ equity through public or private financings, while noting there is no assurance of completing financings, securing a favorable panel decision, or regaining or maintaining Nasdaq compliance.
CERo Therapeutics Holdings, Inc. reported interim results showing limited cash runway, ongoing operating losses and material financing activity. The company had approximately $3.23 million in cash and cash equivalents at June 30, 2025 and an accumulated deficit of approximately $81.4 million. For the six months ended June 30, 2025 the Company recorded a net loss of $5.42 million, and a year-to-date net loss of $10.52 million for 2024 comparisons presented. During the period the Company raised proceeds of approximately $4.2 million from a February 2025 securities offering, $2.9 million from warrant exercises, subscriptions and ELOC fundings, and $2.2 million from sales of Series D preferred stock. The filing discloses substantial doubt about the Company’s ability to continue as a going concern without additional financing. The Company effected reverse stock splits and recorded significant preferred-to-common conversions and related deemed dividends and stock-based inducement expenses that materially affected reported equity and net loss.
CERo Therapeutics Holdings, Inc. filed a notification that it will be late in submitting its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025. The delay stems from ongoing work by management and accounting staff to finalize the valuation and accounting treatment of marketable securities the company received as part of a securities purchase agreement involving Series D preferred stock. CERo expects to file the quarterly report within five calendar days after the original due date.
The company currently estimates a net loss of $18.5 million for the quarter ended June 30, 2025, compared with a net loss of $2.4 million a year earlier. Net loss attributable to common shareholders is estimated at $33.4 million, driven in part by approximately $14.9 million of deemed dividends related to conversions of Series A, B and C preferred stock, the absence of prior-year gains, and an unrealized loss on equity securities, partly offset by lower operating expenses. These results are preliminary and may change when the quarterly report is finalized.
Cero Therapeutics Holdings received a Schedule 13G filing disclosing that Armistice Capital, LLC and Steven Boyd together beneficially own 63,308 shares of the company’s common stock, representing 4.99% of the class. Armistice Capital is the investment manager of a Master Fund that directly holds the shares and, under its Investment Management Agreement, Armistice exercises shared voting and dispositive power over those shares. Mr. Boyd, as managing member of Armistice, is reported to share those voting and disposition powers. The filing states the position is held in the ordinary course of business and not to influence control.